Abstract

Ionis Pharmaceuticals will report its quarterly financial results Pre-Market on February 25, 2026, with investors watching revenue trajectory, margin dynamics, and EPS versus consensus as the company enters a new commercialization phase following recent regulatory progress.

Market Forecast

Based on current-quarter forecasts, Ionis Pharmaceuticals’ revenue is projected at 156.09 million, reflecting year-over-year growth of 13.44%, while EBIT is estimated at -210.27 million (down 19.11% year-over-year) and adjusted EPS is expected at -1.32 (down 17.63% year-over-year); consensus margin forecasts are not disclosed, but last quarter’s gross profit margin of -40.44% and net profit margin of -82.06% provide a baseline for near-term mix and cost analysis. The company’s main business remains centered on commercial activities, with last quarter’s commercial revenue of 115.60 million, and the outlook this quarter tilts toward incremental top-line support from commercial milestones and early product contribution, while operating losses are anticipated to persist.

The most promising segment this quarter is hereditary angioedema prophylaxis anchored by donidalorsen (Dawnzera), recently approved in Europe; reported segment-level year-over-year growth is not available given the nascent launch, but contribution will flow into the commercial line which accounted for 73.76% of last quarter’s total revenue.

Last Quarter Review

Ionis Pharmaceuticals delivered last quarter revenue of 157.00 million, gross profit margin of -40.44%, GAAP net profit attributable to the parent company of -129.00 million, net profit margin of -82.06%, and adjusted EPS of -0.80, with adjusted EPS improving year-over-year by 15.79% amid sustained operating investment.

A key financial highlight was the top-line beat against prior estimates by 26.08 million and an EPS beat of approximately $0.43 per share, underscoring resilient revenue execution despite a deeply negative operating and net margin profile. Main business performance was led by commercial revenue of 115.60 million (73.76% of total), and while segment-level year-over-year growth was not disclosed, total company revenue increased 17.16% year-over-year.

Current Quarter Outlook

Commercial Segment

The commercial segment remains Ionis Pharmaceuticals’ revenue anchor, and last quarter it supplied 115.60 million, equal to 73.76% of total revenue, highlighting the centrality of product-related revenue and collaboration economics to the near-term financial mix. For the current quarter, the market’s revenue forecast of 156.09 million and year-over-year increase of 13.44% implies incremental contributions from commercial streams, including initial post-approval activities and ongoing collaboration receipts. While consensus margin estimates are not provided, last quarter’s gross margin of -40.44% and net margin of -82.06% indicate that cost of revenue and operating expense intensity are still outpacing revenue scale, a dynamic likely to persist short term as Ionis invests in launch and pipeline advancement.

Investors should frame the reported negative margins within the context of a company transitioning from a predominantly R&D-driven model to building durable commercial cash flows, where early launch periods typically reflect heavier logistics, payer onboarding, and market education costs ahead of scaled revenues. The previous quarter’s quarter-on-quarter net profit change of -204.09% underscores how timing of milestones, cost recognition, and launch investments can skew bottom-line comparability, particularly when quarterly revenue is still modest relative to fixed costs. The current quarter will therefore be assessed less on immediate profitability and more on the growth direction of revenue lines, the scale and cadence of commercial receipts, and the extent to which opex aligns with an accelerating product ramp and collaboration-derived cash flows.

From a near-term operating lens, investors will watch for signals pointing to normalization of gross margin as product mix evolves and manufacturing and distribution costs stabilize with volume. Similarly, any commentary about collaboration milestones and royalties recognized during the quarter could help explain deviations in EBIT, which is forecast at -210.27 million (down 19.11% year-over-year). The trajectory of adjusted EPS, expected at -1.32 (down 17.63% year-over-year), will be viewed in the context of top-line momentum against continued investment spending, with revenue execution remaining the most influential variable for sentiment in the commercial line.

Hereditary Angioedema Franchise (Dawnzera)

The hereditary angioedema (HAE) prophylaxis franchise centered on donidalorsen (Dawnzera) is positioned as the largest near-term growth catalyst within Ionis Pharmaceuticals’ portfolio. The European Commission approved Dawnzera for routine prevention of recurrent HAE attacks in adults and adolescents aged 12 and older, and it is self-administered via subcutaneous autoinjector every four or eight weeks—an administration profile designed to meet chronic prophylaxis needs efficiently. This approval follows phase 3 data demonstrating a significant and sustained reduction in mean monthly HAE attack rates, including a 94% reduction at one year observed in the OASISplus open-label extension study, which provides an evidence base supporting clinical adoption.

Market observers will focus this quarter on the early commercialization steps in Europe: the pace of patient onboarding, reimbursement implementation across EU markets, and physician adoption patterns in centers specializing in rare disease and immunology. As Dawnzera’s revenue will be recognized within the commercial line, near-term financial contribution is expected to be modest at launch, but it establishes a durable growth pathway for subsequent quarters as coverage broadens and prescriber familiarity grows. Given European launches typically ramp by geography and payer, qualitatively tracking initial uptake and any early demand signals reported by Ionis will be important for extrapolating the franchise’s trajectory into the second half of the year.

For this quarter specifically, the company’s overall revenue growth forecast of 13.44% year-over-year suggests consensus is already baking in incremental contribution from commercialization activities and collaboration-related receipts; however, the nascent stage of the Dawnzera launch means segment-level year-over-year growth is not directly comparable at this point. The HAE prophylaxis segment’s outlook remains constructive because it can alter Ionis’s revenue composition toward recurring product sales that compound with patient adherence, improving visibility and predictability over time. The autoinjector dosing flexibility, coupled with strong efficacy data, should be supportive of persistence, and the emerging commercial footprint in Europe lays groundwork for potential geographic expansion strategies subject to regulatory pathways and collaborations.

Key Stock-Price Drivers This Quarter

Three elements are likely to shape Ionis Pharmaceuticals’ stock performance around the print: revenue execution versus the 156.09 million forecast, margins and opex commentary, and pipeline/regulatory updates that reinforce confidence in upcoming revenue streams. Revenue outperformance relative to the 13.44% year-over-year consensus growth would reinforce the premise that commercial launches and milestones are beginning to scale, which could offset negative EPS optics driven by investment spending. Conversely, shortfalls in top-line could amplify scrutiny of the timing of collaboration revenue recognition and the early commercialization cadence, especially with EBIT estimated at -210.27 million.

Margin commentary will be parsed carefully. With last quarter’s gross margin at -40.44% and net margin at -82.06%, investors will look for management’s explanations of cost of revenue, mix effects, and the path toward margin improvement as product revenues mature. Any disclosed adjustments in operating cost structure or the sequencing of launch-related expenses could serve as leading indicators for when adjusted EPS might begin to trend closer to breakeven over a longer horizon, though the current quarter’s -1.32 forecast suggests continued losses while growth investments remain elevated.

Pipeline and regulatory momentum adds a stabilizing component to sentiment. The recent European approval of Dawnzera supports a clearer revenue story, while updates tied to partnered programs—such as the reported positive Phase 3 outcomes for bepirovirsen in chronic hepatitis B with GSK—can broaden future milestone and royalty prospects. In aggregate, these developments strengthen the medium-term commercial narrative even if the current quarter’s P&L remains loss-making. As a result, sell-side and institutional focus this quarter is likely to center on whether revenue growth beats consensus, how management frames the cost trajectory accompanying launch builds, and how the pipeline cadence underwrites visibility into revenue stacking across 2026.

Analyst Opinions

The balance of recent institutional views is decisively favorable; within the January–February window, published opinions tracked are bullish with no bearish calls, making the ratio of bullish to bearish effectively 1 to 0. RBC Capital’s Luca Issi maintained a Buy rating on Ionis Pharmaceuticals and set a target price of $95.00, reflecting confidence in the company’s emerging commercial story and the validation provided by regulatory progress. This stance aligns with the setup into the quarter: a forecast for revenue of 156.09 million, year-over-year expansion of 13.44%, and a strengthening catalyst framework anchored by the new HAE prophylaxis approval.

Analyzing the RBC perspective in the context of current-quarter expectations, the emphasis appears to be on two pillars of execution: demonstrable revenue growth from commercial activities and steady advancement across partnered programs that can translate into milestones and royalties. The former is reinforced by last quarter’s revenue beat of 26.08 million and the dominance of commercial revenue at 115.60 million, which indicate that Ionis has begun establishing a recognizable base for product-linked cash flows. The latter, highlighted by positive Phase 3 outcomes in hepatitis B with GSK and recent EU approval in HAE, helps mitigate concerns stemming from negative EBIT (-210.27 million estimate) and adjusted EPS (-1.32 estimate), by strengthening longer-term revenue visibility.

From a market narrative perspective, bullish institutions are typically looking through near-term losses when the trajectory for top-line growth is improving and the runway for additional revenue layering is becoming clearer. In this framework, consensus sees a quarter where EBIT and EPS remain negative but are paired with revenue increasing 13.44% year-over-year, a combination consistent with a transition period characterized by launch spending and pipeline investment. The majority bullish view contends that as geographic commercialization progresses for Dawnzera and collaboration economics materialize in cadence, the revenue base will expand and gradually provide leverage, even if margins are depressed in the near term.

Furthermore, the RBC rating underscores the importance of qualitative signals management may provide on launch traction, payer engagement, and quarterly sequencing of commercialization activities. Such detail will be essential for institutional models to calibrate the slope of revenue growth for the commercial segment—which delivered 115.60 million last quarter—and to contextualize adjusted EPS trends against spending patterns. In sum, the prevailing analyst sentiment is that Ionis Pharmaceuticals enters this quarter with strengthening revenue prospects and meaningful catalysts, and the upcoming report will be judged on the degree to which revenue meets or exceeds the 156.09 million projection and whether management’s margin and opex narrative vis-à-vis launch costs supports confidence in the revenue growth profile for the remainder of 2026.